$CLDI News

Calidi Biotherapeutics Q1 EPS $(0.43) Beats $(1.56) Estimate

Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI

Calidi Biotherapeutics Collaborates With TransferAI To Advance Its IND Submission For CLD-401 By Using The Sofie Proprietary Agentic AI Platform

RedChip's Biotech Virtual Investor Conference Replays Now Available

Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026

Calidi Biotherapeutics shares are trading lower. The company announced that it expects to file an FDA Investigational New Drug application for its lead candidate, CLD-401, by the end of 2026.

Calidi Biotherapeutics shares are trading lower. The company announced that it expects to file an FDA Investigational New Drug application for its lead candidate, CLD-401, by the end of 2026.

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Calidi Showcases RedTail Platform Data Highlighting Dual T-Cell Activation Strategy For Solid Tumors At AACR 2026

Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy

RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy

Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026

Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Calidi Biotherapeutics To Present New Data On Its Approach Of Simultaneously Activating T-Cells At American Association Of Cancer Research Annual Meeting

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials

Calidi Biotherapeutics Partners With Avance Clinical On Initiating First-In-Human Clinical Trial For CLD-401 In Australia

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing